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epidemiology of the speciﬁ c disease, the adoption and diffusion rate of new drug, etc. 
Drug cost is expressed as the monthly cost of new and/or existing drugs. Treatment 
duration is the average months of patient remained on new and/or existing drugs 
which could be derived from clinical trials or clinical observations. Person-time on 
treatment is calculated by multiplying (1) and (2) and be allocated to respective budget 
year, then multiple (3) to obtain the annual cost of new and/or existing treatment. 
The net ﬁ nancial impact is the annual cost difference between new and existing treat-
ment. CONCLUSIONS: The framework is simple and ﬂ exible, feasible for most new 
drug applications to estimate likely ﬁ nancial impact. It has been adopted by recently 
revised new drug reimbursement application form of NHI. The working tool is freely 
available as an option for calculation. 
ME4
DEVELOPMENT OF STANDARD COST LIST FOR ECONOMIC 
EVALUATION IN THAILAND
Riewpaiboon A1, Koopitakkajorn T1, Kumluang S1, Chaikledkaew U2, Khiaocharoen O3
1Mahidol University Faculty of Pharmacy, Bangkok, Thailand; 2Division of Social and 
Administrative Pharmacy, Bangkok, Thailand; 3Naresuan University Faculty of Medicine, 
Pitsanuloke, Thailand
OBJECTIVES: The objectives of this study were to develop the relative value units 
(RVUs) and unit costs of hospital health services employing the RVU method for 
economic evaluation in Thailand. METHODS: The RVUs were developed by using 
the objective data method based on the reimbursable price list of the Civil Service 
Medical Beneﬁ t Scheme. For non-reimbursable health promotion and prevention 
services, unit costs were calculated at a selected hospital for RVU development. To 
test the RVUs, the unit costs calculated by RVU method were compared to those 
computed by conventional micro-costing method. Then, the RVUs were used to cal-
culate standard unit costs of health services. Three district hospitals and three provin-
cial hospitals where met the developed efﬁ ciency criteria were selected for the 
calculation. Total hospital cost including labor, material and capital costs and exclud-
ing pharmacy cost was calculated. Total RVUs were calculated by the summation of 
the multiplication of number of health services provided and its RVU. Total cost was 
divided by the total RVUs resulting in cost per RVU. Finally, unit cost of each service 
was calculated by the multiplication of number of RVUs and cost per RVU. RESULTS: 
This study results in RVUs of 3091 health service items which were classiﬁ ed into 12 
groups. Unit cost of each service classiﬁ ed by types of hospitals was provided. A web-
based standard unit cost list was created and could be accessible to the public. 
CONCLUSIONS: This study developed the ﬁ rst list of standard unit cost of health 
services of district and provincial hospitals in Thailand. The standard unit cost list is 
an important tool for providing cost inputs when performing economic evaluation of 
health interventions and it helps standardize and improve the quality of economic 
evaluation studies in Thailand. 
PODIUM SESSION II: CARDIOVASCULAR DISEASE STUDIES
CV1
USING REAL WORLD DATA TO CALCULATE THE COST-EFFECTIVENESS 
OF STATIN AMONG PARTICIPNATS WITH ATHEROTHROMBOTIC 
DISEASE IN AUSTRALIAN GENERAL PRACTICE
Ademi Z1, Liew D2, Hollingsworth B1, Steg PG3, Bhatt D4, Reid C1
1Monash University, Melbourne, Australia; 2The University of Melbourne, Fitzroy, Victoria, 
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OBJECTIVES: The use of statin has been shown to be cost effective in the secondary 
prevention of coronary heart disease and cerebrovascular disease. However, a “treat-
ment gap” exists, whereby many eligible patients do not receive statin therapy. We 
sought to determine the cost-effectiveness of closing this treatment gap in the Austra-
lian healthcare setting. METHODS: Analysis was based on 4-year follow-up data from 
Australian participants of the Reduction of Atherothrombosis for Continued Health 
(REACH) Registry. Subjects were aged 345 years and had established atherothrom-
botic disease, comprising coronary artery disease (CAD), and cerebrovascular (CerVD) 
disease. Decision analysis was applied to compare current coverage with statin against 
a hypothetical situation whereby all subjects were assumed to be treated. Outcomes 
of interest were nonfatal stroke, nonfatal myocardial infraction (MI), and cardiovas-
cular deaths. The relative changes to the risks of these outcomes conferred by statin 
were derived from published meta-analysis. Costs were based on government-reim-
bursed data for 2009. RESULTS: Among the sample of 2768 participants, coverage 
with statin therapy was between 63% and 82%, depending on age group. Over the 
4-year period, 89, 101, and 146 nonfatal strokes, nonfatal MIs, and cardiovascular 
deaths were observed, respectively. Assuming that all subjects had taken statin, the 
predicted equivalent numbers were 85, 96, and 137 respectively. The estimated incre-
mental cost-effectiveness ratio (ICER) for CAD subjects was AUD $45,274 per life-
year gained (LYG). For CerVD subjects, the ICERs were AUD $40,738. Equating to 
numbers needed to treat of 136 and 99.5. Sensitivity analysis showed that the results 
were robust. CONCLUSIONS: The results of this model suggest that for subjects with 
athethrombotic disease, maximizing coverage with statin, in line with evidence-based 
recommendations, represents a cost-effective means of secondary prevention. 
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ATTRIBUTABLE COST AND LENGTH OF STAY FOR PATIENTS WITH 
ENOXAPARIN-ASSOCIATED BLEEDING
Khaisombat N1, Saokaew S2, Chaiyakunapruk N3, Nathisuwan S1
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OBJECTIVES: Patients receiving enoxaparin are at risk of bleeding. However, the 
study of the ﬁ nancial impact of enoxaparin-associated bleeding is limited. This study 
aims to estimate the attributable costs and length of stay (LOS) of patients with 
enoxaparin-associated bleeding (EAB) compared with non-bleeding patients (NB). 
METHODS: We conducted a retrospective cohort study of hospitalized acute coro-
nary syndrome patients who received enoxaparin since January 2006 to February 
2009 in a large University-afﬁ liated hospital. Cost and LOS were compared between 
patients with and without EAB on both univariable and multivariable analyses. In 
multivariable analysis, the attributable cost and LOS were estimated using a multiple 
linear regression with log-transformed model and adjusted by propensity score (PS), 
which was predicted by patient’ characteristics including age, gender, history of bleed-
ing, hypertension, stroke, diabetes, creatinine clearance, and congestive heart failure 
(CHF) at admission. The adjusted means of cost and LOS estimates were retrans-
formed to their natural values using Duan’s smearing estimator. The differences of 
costs and LOS were presented as mean with 95% conﬁ dence intervals. RESULTS: 
Out of 346 patients, 134 (38.7%) experienced enoxaparin-associated bleeding. The 
average age and comorbidities in both groups were similar. However, in EAB group 
had more male than NB group (42% vs. 30%). Based on univariable analyses, the 
attributable cost and LOS of patients with EAB were 68,875 THB ($2152) and 4.2 
days, respectively. Based on PS-adjusted multivariable regression analyses, the cost 
and LOS attributable to EAB was 80,644 THB ($2520) (95% CI: 69,879 ($2184) to 
91,408 ($2857) and 3.4 days (95% CI: 3.0 to 3.7), respectively. CONCLUSIONS: 
Bleeding is associated with increased cost and LOS among enoxaparin users. These 
ﬁ ndings suggest that strategies that reduce the risk of bleeding have the potential 
important reductions in costs of care for enoxaparin users. 
CV3
COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR 
PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL 
KNEE REPLACEMENT (TKR) IN CHINA
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban against enoxaparin 
for prevention of venous thromboembolism (VTE) following total knee replacement 
(TKR) in China. METHODS: An economic model was developed, consisting of three 
modules: prophylaxis, post-prophylaxis, and long-term complications. The ﬁ rst two 
modules were represented using a decision tree while the third module used a Markov 
process. Safety and efﬁ cacy data during prophylaxis were derived from a Phase III inter-
national multi-regional registration trail (RECORD 3). Utility outcomes and the probabil-
ity of long-term events were based on systematic review and published data. Resource use 
related to VTE prevention, treatment and complications was based on clinical guidelines, 
product labels, and interviews conducted in six Tier 3 hospitals in Beijing, Shanghai and 
Guangzhou City. Unit cost data were collected from government pricing bureau and 
presented in 2009 CNY from the health-care system perspective. Costs and outcomes were 
discounted at 3% per annum. Extensive one-way probabilistic sensitivity analyses were 
undertaken. RESULTS: In the base case analyses, rivaroxaban was shown to be domi-
nant compared with enoxaparin. Rivaroxaban was associated with 0.0019 additional 
QALYs per patient while saving an average of CNY 242 per patient over 5 years. 
Costs associated with VTE clinical events were lower in rivaroxaban group (CNY 
581) compared with the enoxaparin group (CNY 1059). Probabilistic sensitivity 
analyses estimated that rivaroxaban had a probability of >90% of being cost-effective 
compared with enoxaparin at a low willingness-to-pay threshold of CNY 20,000 per 
QALY gained. CONCLUSIONS: Compared with enoxaparin, rivaroxaban improved 
patients’ health outcomes and produced overall cost savings in VTE prevention after 
TKR in China. 
CV4
THE CLINICAL EFFECTIVENESS OF 64-SLICE OR HIGHER COMPUTED 
TOMOGRAPHY ANGIOGRAPHY AS AN ALTERNATIVE TO INVASIVE 
CORONARY ANGIOGRAPHY IN THE INVESTIGATION OF SUSPECTED 
CORONARY ARTERY DISEASE
Paech D, Weston A
Health Technology Analysts Pty Ltd, Sydney, NSW, Australia
OBJECTIVES: This systematic review was conducted for The New Zealand Ministry 
of Health to summarize recent evidence pertaining to the clinical effectiveness of 
64-slice or higher computed tomography angiography (CTA) in patients with sus-
pected coronary artery disease (CAD). If CTA proves to be a successful diagnostic 
performance measure, it could prevent the application of invasive diagnostic proce-
dures in some patients. This would provide multiple health and cost beneﬁ ts, particu-
larly for under resourced District Health Boards where invasive coronary angiography 
is not always available. METHODS: A systematic method of literature searching and 
selection was employed with searches limited to December 2006 to March 2009. 
Included studies were quality assessed using NHMRC diagnostic levels of evidence 
and a modiﬁ ed QUADAS tool. Individual and pooled diagnostic performance mea-
sures (i.e., sensitivity, speciﬁ city, positive predictive value (PPV), negative predictive 
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value (NPV) and overall diagnostic accuracy) were calculated at the patient, vessel 
and segment level. RESULTS: This systematic review included 28 studies. The base 
case meta-analysis at the patient-level indicated a sensitivity of 98.2%, speciﬁ city of 
81.6%, PPV of 88.9%, NPV of 96.8%, and diagnostic accuracy of 91.6%. In all 
vessels, the pooled sensitivity was 95.0%, speciﬁ city 85.2%, PPV 69.4%, NPV 97.9%, 
and diagnostic accuracy 87.7%. At the individual artery level, overall diagnostic 
accuracy appeared to be slightly higher in the left and right coronary artery and slightly 
lower in the left anterior descending and circumﬂ ex artery. In all segments, the sensitiv-
ity was 91.1%, speciﬁ city 94.3%, PPV 65.7%, NPV 98.9%, and overall diagnostic 
accuracy 94.0%. CONCLUSIONS: The high sensitivity observed in this update indi-
cates that CTA can effectively identify the majority of patients with signiﬁ cant coro-
nary artery stenosis. The high NPV at the patient, vessel and segment level establishes 
CTA as an effective noninvasive alternative to ICA for the exclusion of stenosis. 
PODIUM SESSION II: DIABETES STUDIES
DB1
EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION 
FROM BASAL INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN 
PATIENTS WITH TYPE 2 DIABETES IN CHINA: A MODELING STUDY OF 
LONG-TERM COSTS AND HEALTH OUTCOMES
Chang J1, Sun F1, Li H2
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OBJECTIVES: To evaluate the long-term cost-effectiveness of switching from basal 
insulin to biphasic insulin aspart 30 (BIAsp30) in patients with type 2 diabetes (T2D) 
in China. METHODS: A published and validated computer simulation model of 
diabetes (CORE Diabetes Model) was used to project long-term (30 years) of health 
and economic outcomes. Simulated cohorts and treatment effects were derived from 
a 16-week, multi-center, and single-arm trial-NCT00669864 which investigated the 
efﬁ cacy and safety of BIAsp30 ± Metformin in T2D patients inadequately controlled 
with basal insulin. Two subgroups of basal insulin treatment were categorized as 
insulin glargine (IGla) ± Metformin and neutral protamine hagedorn (NPH) insulin ± 
Metformin. The market retail prices of medications were calculated to estimate treat-
ment costs. The diabetes management and complications costs were obtained from 
Chinese published data. An annual discounting rate of 3% was used for both costs 
and health outcomes. One-way sensitivities analysis was performed. RESULTS: 
Therapy conversion to BIAsp30 was projected to improve life expectancy signiﬁ cantly 
in comparison with IGla (0.347 ± 0.245 years), and NPH (0.452 ± 0.242 years). 
Transfer to BIAsp30 was associated with improvements in 0.327 quality-adjusted 
life-years (QALYs) over IGla, and 0.393 QALYs over NPH. Therapy conversion to 
BIAsp30 reduced medical costs by Chinese Yuan (CNY) 46,540 per patient compared 
to IGla. However, it increased CNY 19,525 compared to NPH and was associated 
with an incremental cost-effectiveness ratio of CNY 49,730 per QALY gained. CON-
CLUSIONS: Therapy conversion from basal insulin to BIAsp30 in T2D patients in 
China was associated with improvements in life expectancy and QALYs. Transfer to 
BIAsp30 was cost-saving treatment strategy in T2D patients managed with IGla, and 
would be considered cost-effective in T2D patients managed with NPH, given a 
willingness-to-pay threshold of CNY 75,375 per QALY (three times GDP per capita 
in 2009) gained in China. 
DB2
TRANSLATION AND VALIDATION OF MICHIGAN DIABETES 
KNOWLEDGE SCALE INTO MALAYSIAN VERSION
Al-Qazaz HK1, Hassali MA1, Shaﬁ e AA1, Sulaiman SA1, Sundram S2
1Universiti Sains Malaysia, Minden, Penang, Malaysia; 2Hospital Balik Pulau, Balik Pulau, P.Penang, 
Malaysia
OBJECTIVES: To translate the Michigan Diabetes Knowledge Scale (MDKT) into the 
Malaysian language, and to examine the psychometric properties of the Malaysian 
version of the MDKT among patients with type 2 diabetes, including its validity and 
reliability. METHODS: After obtaining permission, a standard “forward-backward” 
translation procedure was used to create the Malaysian version of the MDKT from 
the original English version. A convenience sample of 307 outpatients with type 2 
diabetes was identiﬁ ed between May and October, 2009. All data were collected from 
the Penang General Hospital, Penang, Malaysia. Instruments consisted of the Malay-
sian version of MDKT and a socio-demographic questionnaire. Medical records were 
reviewed for hemoglobin A1C (HbA1C) levels and other clinical data. Reliability was 
tested for internal consistency using Cronbach’s α coefﬁ cient. Validity was conﬁ rmed 
using known group validity. RESULTS: Employing the recommended scoring method, 
the mean ± SD of MDKT scores was 7.88 ± 3.01. Good internal consistency was 
found, (`’s α = 0.702), the test–retest reliability value by using Spearman’s rank cor-
relation was 0.894 (P < 0.001). For known group validity, a signiﬁ cant relationship 
between MDKT categories and HbA1c categories (×2 = 21.626; P ≥ 0.001) was found. 
CONCLUSIONS: The MDKT can be used for diabetes knowledge assessment in 
diabetes. The ﬁ ndings of this validation study indicate that the Malaysian version of 
the MDKT is a reliable and valid measure of medication adherence which can now 
be used in clinical and research practice. 
DB3
LIFETIME CLINICAL PROJECTIONS FOR OVERWEIGHT OR OBESE 
SUBJECTS WITH IMPAIRED GLUCOSE INTOLERANCE BASED ON THE 
LONG TERM RESULTS OF THE DIABETES PREVENTION PROGRAM AND 
DIABETES PREVENTION PROGRAM OUTCOMES STUDY
Palmer AJ, Tucker DM
Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia
OBJECTIVES: Metformin and intensive lifestyle interventions (ILI) were shown to 
reduce incidence of type 2 diabetes (T2D) versus standard care in overweight or obese 
subjects with impaired glucose tolerance (IGT) in the Diabetes Prevention Program 
(DPP) trial and Diabetes Prevention Program Outcomes Study (DPPOS), a total fol-
low-up of 10 years. Our aim was to project the lifetime clinical outcomes to be 
expected from T2D prevention in high-risk subjects treated with standard care, met-
formin or ILI, based on the results from the DPP + DPPOS. METHODS: A semi-
Markov, second-order Monte Carlo model was developed to project the 10-year 
clinical results of the DPP + DPPOS to patient lifetimes. Speciﬁ cally, we calculated 
years free of T2D, cumulative incidences of T2D, and nondiscounted life expectancies 
in subjects who were initiated on diabetes prevention regimens based on metformin, 
ILI or standard care. Four health states were modeled: normoglycemia (NG); IGT; 
T2D and dead. Subjects started in IGT and progressed to T2D or NG, at rates depen-
dent on the treatment received. State-speciﬁ c mortality rates for NG, IGT or T2D were 
used. Univariate and probabilistic sensitivity analyses were performed. RESULTS: For 
standard care, metformin or ILI, mean (standard deviation) number of years free of 
T2D were 9.47 (0.08), 11.98 (0.09), 15.17 (0.11) years respectively. Cumulative 
incidences of T2D were 89.7% (0.2), 83.7% (0.2) and 73.4% (0.3%) for standard 
care, metformin or ILI respectively. Mean life expectancies from baseline age of 50 
years were 27.64 (0.14), 27.95 (0.12), 28.33 (0.11) years for standard care, metformin 
or ILI respectively. Results were most sensitive to the relative risk reduction in the 
incidence of T2D and relative risks of mortality in the T2D state versus IGT state. 
CONCLUSIONS: Substantial improvements in lifetime clinical outcomes can be 
expected in high risk subjects treated with metformin or ILI to delay or prevent the 
onset of T2D. 
DB4
ECONOMIC EVALUATION OF THIAZOLIDINEDIONES AS ADD-ON 
THERAPY FOR TREATMENT OF TYPE 2 DIABETIC PATIENTS IN THE 
TAIWANESE NATIONAL HEALTH INSURANCE SYSTEM
Hsiao FY1, Mullins CD1, Huang WF2
1University of Maryland School of Pharmacy, Baltimore, MD, USA; 2Institute of Health & 
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OBJECTIVES: The cost-effectiveness of adding thiazolidinediones (TZDs), rosigli-
tazone or pioglitazone, to metformin in treating type-2 diabetes mellitus was assessed 
from a Taiwanese national health insurance perspective. METHODS: This analysis 
was based on patient-level data extracted from the 2000–2005 Taiwan’s National 
Health Insurance (NHI) databases. Type 2 diabetic patients who had their ﬁ rst ambu-
latory visits with a diagnosis of diabetes mellitus and had received consecutive met-
formin treatments between 2001 and 2005 were identiﬁ ed. Clinical effectiveness, a 
proxy of glycemic control (time to insulin dependence), and direct medical cost also 
were estimated from the NHI databases. Incremental cost-effectiveness ratio (ICER) 
was calculated and expressed as cost per delayed year to insulin dependence. 
RESULTS: The use of TZDs as add-on therapy compared non-TZDs add-on therapy 
was associated with a delay in time to insulin dependence, rosiglitazone was associated 
with an additional 151 days (0.41 years) and pioglitazone was associated with an 
additional 101 days (0.28 years) of delay in insulin dependence. During the follow-up 
period, total mean medical costs were higher in patients who received an add-on 
rosiglitazone (New Taiwan dollars (NT) 153,162) or pioglitazone (NT 139,931) 
compared to add-on non-TZDs (NT 113,492) and the additional medical costs were 
driven primarily by diabetic medication cost and outpatient visit costs. Combining the 
cost and effectiveness results, the ICER showed that the additional total medical costs 
of add-on rosiglitazone or pioglitazone were comparable, with ICERs of 95,874 and 
95,485 NT dollars per year delay in insulin dependence, respectively. CONCLU-
SIONS: This analysis suggests that add-on rosiglitazone or pioglitazone improves 
glycemic control but also increases direct medical costs compared with add-on non-
TZDs when used in type-2 diabetic patients. In terms of the incremental medical costs 
associated with these clinical beneﬁ ts, add-on rosiglitazone or pioglitazone are similar 
in the National Health Insurance system in Taiwan. 
PODIUM SESSION II: DATABASE STUDIES
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ESTIMATING ADHERENCE AND PERSISTENCY OF ANTIDEPRESSANTS 
USING THE KOREA NATIONAL HEALTH INSURANCE CLAIMS 
DATABASE
Jung SY, Song H, Shin S, Shin E, Park J1, Ahn J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
OBJECTIVES: To investigate adherence and persistence of antidepressants (ADs) 
among the patients with depression in Korea. METHODS: Using the Korean Health 
Insurance Review & Assessment Service (HIRA) claims database (2006–2008), 
patients aged 18–84 with at least one inpatient or two outpatient diagnoses of depres-
